# A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

> **NCT05718921** · PHASE1 · COMPLETED · sponsor: **Hangzhou Yirui Pharmaceutical Technology Co., Ltd** · enrollment: 54 (actual)

## Conditions studied

- Atopic Dermatitis
- Psoriasis

## Interventions

- **DRUG:** YR001 Dose A on low body surface area
- **DRUG:** YR001 Dose A on middle body surface area
- **DRUG:** YR001 Dose A on high body surface area
- **DRUG:** YR001 Dose B on low body surface area
- **DRUG:** YR001 Dose B on middle body surface area
- **DRUG:** YR001 Dose B on high body surface area
- **DRUG:** Placebo on low body surface area
- **DRUG:** Placebo on middle body surface area
- **DRUG:** Placebo on high body surface area
- **DRUG:** YR001 Dose A on high body surface area twice daily
- **DRUG:** YR001 Dose B on high body surface area twice daily
- **DRUG:** Placebo on high body surface area twice daily

## Key facts

- **NCT ID:** NCT05718921
- **Lead sponsor:** Hangzhou Yirui Pharmaceutical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-08
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718921, "A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05718921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*